Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy-Reference-Cited by-同舟云学术

Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy

Published:2024-01-01 Issue:1 Volume:26 Page:49-58
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Lepore Giuseppe¹,Borella Nicolò Diego¹,Castagna Giona¹²,Ippolito Silvia¹,Bonfadini Silvia¹,Corsi Anna¹,Scaranna Cristiana¹,Dodesini Alessandro Roberto¹,Bellante Rosalia¹,Trevisan Roberto¹²

Affiliation:

1. Unit of Endocrine Diseases and Diabetology, Department of Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.

2. Department of Medicine, Università degli Studi di Milano-Bicocca, Milan, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2023.0261

Reference35 articles.

1. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

2. Six-Month Effectiveness of Advanced vs. Standard Hybrid Closed-Loop System in Children and Adolescents With Type 1 Diabetes Mellitus

3. Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4’120 Users

4. Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus

5. MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience;European Journal of Medical Research;2024-07-15